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Abstract: The potential of MR thermometry (MRT) fostered the development of MRI compatible
radiofrequency (RF) hyperthermia devices. Such device integration creates major technological
challenges and a crucial point for image quality is the water bolus (WB). The WB is located between
the patient body and external sources to both couple electromagnetic energy and to cool the patient
skin. However, the WB causes MRT errors and unnecessarily large field of view. In this work,
we studied making the WB MRI transparent by an optimal concentration of compounds capable
of modifying T2* relaxation without an impact on the efficiency of RF heating. Three different T2*
reducing compounds were investigated, namely CuSO4, MnCl2, and Fe3O4. First, electromagnetic
properties and T2* relaxation rates at 1.5 T were measured. Next, through multi-physics simulations,
the predicted effect on the RF-power deposition pattern was evaluated and MRT precision was
experimentally assessed. Our results identified 5 mM Fe3O4 solution as optimal since it does not alter
the RF-power level needed and improved MRT precision from 0.39 ◦C to 0.09 ◦C. MnCl2 showed a
similar MRT improvement, but caused unacceptable RF-power losses. We conclude that adding Fe3O4
has significant potential to improve RF hyperthermia treatment monitoring under MR guidance.
Keywords: hyperthermia; MR thermometry; MRI guided interventions; dielectric properties;
MRI properties; water bolus
1. Introduction
Clinical trials have shown that the clinical outcome and local control of chemotherapy and
radiotherapy treatments can be enhanced with the addition of hyperthermia treatments [1–5].
Clinically demonstrated thermal dose effect relationship indicate that the efficacy of the hyperthermia
treatment improves when achieving higher temperatures in the 40–44 ◦C range in the entire
target, while preventing unacceptable temperature increases in healthy tissues, i.e., “hotspots”.
Advances in hyperthermia technologies improved the delivery of the treatment [6–8]. Electromagnetic
radiofrequency systems consists of multiple antennas organized in an annular array configuration and
using constructive interference provides focused energy deposition at depth, whereby the location of
the focus can be dynamical adapted using phase and amplitude control per antenna [9,10]. For deep
pelvic heating, the frequency range is 70–120 MHz, for deep heating of head and neck tumors the
frequency range is 400–600 MHz. A multi-functional water bolus is used to reduce the antenna size,
cool the skin and obtain a preferential energy transfer to the tissue. These advanced heating systems
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are clinical applied in combination with hyperthermia treatment planning guided focus steering.
However, the inhomogeneous, variable and subject dependent thermoregulation mechanisms make
that real-time temperature monitoring is required for optimal guidance of the heating adaptations.
Magnetic resonance thermometry (MRT) provides a non-invasive way to map relative temperature
change pattern in the regions of interest [11,12]. The need for non-invasive temperature monitoring and
the potential of MRT fostered the development of novel magnetic resonance imaging (MRI) compatible
hyperthermia applicators [13]. Such integration of a hyperthermia device into an MR scanner is not a
trivial task and is accompanied by additional requirements and needs for these hybrid devices [14–16].
One of the issues that arise is caused by the hyperthermia device’s water bolus (WB). While the WB
is a trivial component in non-MRI compatible hyperthermia applicators, it causes an unnecessary
increase in the imaging field of view, creates flow artifacts and skews pre-scan calibrations, resulting in
temperature errors and a longer scan time [9]. Solving these WB induced issues may form a large step
towards reaching the full potential of MRI guided hyperthermia treatments, but our knowledge on the
optimum WB filling is incomplete.
The WB is a fluid filled flexible “bag” that can conform to the skin and covers the space between
antennas and patient. De-ionized, i.e., demineralized, water is usually used as filling material due to its
large availability, high biocompatibility, and low losses. The WB has a pivotal role in a radiofrequency
(RF) hyperthermia applicator. The water matches the dielectric properties of the patient better and
thus enables efficient transfer of the radiofrequency waves from the device’s antennas into the patient.
The water is circulated to cool so called “hotspots”, i.e., locations with high power absorption that
often occur near the patient’s skin. Water as a fluid also easily follows the body contour which
is essential for impedance matching and surface cooling. It can also be used to cool the antennas.
The water is also applied to reduce the effective dielectric value of the medium surrounding the
antennas, which decreases the resonant antenna size considerably and enables including more antennas
in the applicator [17]. Unfortunately, the water also comes at a cost when used for MR guided
hyperthermia. Hydrogen in water is the main source of MRI signal in the patient and the imaging
field of view needs to cover also the WB to prevent aliasing in the MR image. Also, pre-MRI-scan
calibrations and MRI RF (B1) field shaping are distorted since also the signal in the large WB is
optimized by these automatic routines. Moreover, water circulation results in flow artifacts in the
differential MRT images. It would be ideal if these problems could be avoided by a WB that is (nearly)
invisible to MRI while preserving its benefits for hyperthermia, i.e., keeping the desired matching and
cooling characteristics.
WB MRI invisibility can be reached by several methods. A simple solution can be achieved by
using heavy water (deuterium oxide, D2O = 2H2O) instead of demineralized water (H2O). Heavy
water is invisible in 1H MRI while having the same electromagnetic properties [18]. However, the
required volume to fill a typical WB is large and heavy water is very expensive. Another method is
by altering the MRI method by inversion recovery (IR) techniques, which are widely used in MRI
applications to suppress water or fat signal. Using an IR sequence to suppress the signal from the
WB, however, this will also suppress the water signal in the body that is used to measure the proton
resonance shift in MRT. Another way to selectively suppress the WB signal is by selective excitation of
the region of interest using two dimensional RF pulses [19]. Grissom et al. recently showed that two
dimensional RF pulses can be used to reduce temperature errors related to the water bath and water
bath motion for transcranial MR-guided focused ultrasound (MRgFUS) ablation. They reported on
average 43% improvement in temperature precision [20]. While this technique shows promise, it is
spatially limited to a single dimension.
While the previous methods (D2O, IR and spatial selective pulses) utilized modification of the
longitudinal relaxation (T1), we hypothesized that modification of the transverse relaxation (T2 or
T2* for gradient echo sequences) of water signal can be an easier, cheaper and more feasible solution.
Several studies have exploited contrast agents to reduce the WB T2* relaxation time. Manganese
chloride (MnCl2) was used by Delannoy et al. [14] for hyperthermia and Chopra et al. [21] for MR
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guided high intensity focused ultrasound (HIFU). Allen et al. have proposed the use of suspending
iron oxide nanoparticles (SPIO) to suppress water bath signal for MRgFUS surgery and reported that
SPIO doped water weakly attenuates acoustic waves [22]. Although these studies showed promising
results, no data are available on their effect on electromagnetic material properties, which are pivotal
for efficient MR guided RF hyperthermia. Also, the effect of additives to the water on therapy and the
optimal concentration or compound has never been researched.
In this study, we investigated the benefit of T2* reducing additives in terms of MRI signal reduction
while maintaining RF properties for different solutions aimed at their application in the WB during
MRI guided RF hyperthermia treatments. Water solutions were prepared with compounds that are
known for their T2* reducing properties; CuSO4, MnCl2, and Fe3O4. We measured electromagnetic
properties 50–600 MHz range and T2* relaxation rates at 1.5 T. Through multi-physics simulations,
we evaluated the predicted effect on the power deposition pattern when the WB filling electromagnetic
properties changed to the measured ones for two MR compatible hyperthermia applicators. Further,
we identified the compounds and concentrations that fulfill the criteria for power efficiency, power
deposition patterns and MR images. Finally, the suitable solutions were experimentally tested in a
clinical setup of the prototype MRcollar [23] and their effect on MRT precision were assessed.
2. Materials and Methods
2.1. Requirements for the Water Bolus Fluid
An ideal WB for MRI guided hyperthermia treatments should have similar electromagnetic
properties as deionized water while producing no or limited MRI signal and artifacts. Demineralized
water filled WB are generally used because of its low losses at the working frequency of hyperthermia
applicators, e.g., at 434 MHz the electrical conductivity is equal to 0.04 S/m. Increase in conductivity
results in an increase of the power needed to achieve a therapeutic specific absorption rate (SAR)
level within the tumor. At Erasmus MC, available amplifiers can provide maximum of 1800 W of RF
power. Hence total required power should be below the maximum available power. However, the
ideal WB solution should be energy efficient and should not cause a drastic power requirements. The
requirements for MRI invisible WB can be achieved when the signal-to-noise ratio (SNR) level of the
WB signal drops to 1. Currently in our clinic, dual echo gradient echo sequence with the body coil
utilized for receiver has been used for MRT with echo times 4.8 ms and 19.1 ms [24]. Hence, for our
setup, we desire SNR of the WB signal should be 1 at the echo time 4.8 ms. Since this will ensure the
SNR at echo times longer than 4.8 ms to be 1 as well.
2.2. Preparation of the Samples
Three different compounds were selected [14,21,22] that are used to modify T2; CuSO4
(Stock# 102791, Merck KGaA, Darmstadt, Germany), MnCl2 (Stock# 244589, Merck KGaA, Darmstadt,
Germany), and Fe3O4 (Stock# US7568, US-Nano-Research, Houston, TX, USA). Six different
concentrations for each compound were selected: [50, 100, 250, 500, 1000, 1250 mM] for CuSO4,
[0.5, 1, 2.5, 5, 12.5, 25 mM] for MnCl2, and [0.25, 0.5, 1, 2.5, 5, 10 mM] for Fe3O4. The temperature of
the water bolus during treatment range from 20 to 30 ◦C. The EM and MRI properties in this range is
relatively stable and changes less than 1% [25,26]. Therefore, all the measurements were made at 21 ◦C,
at the room temperature. The solutions were prepared by diluting the compounds with demineralized
water. The samples were stored in 200 mL measurement cups (diameter 60 mm, height 85 mm).
2.3. MR Relaxometry Measurements
T2* relaxation times of CuSO4, MnCl2, and Fe3O4 solutions for 1.5 T were measured using a 450w
MR scanner (GE Healthcare, Waukesha, WI, USA ) at 21 ◦C. Data acquisition was made with a multi
echo gradient echo sequence with the following sequence parameters: TR = 300 ms, TE = [1.3, 2.8, 4.3,
5.8, 7.3, 8.8, 10.3, 11.8, 13.3, 14.8, 16.3 ms], FOV = 360 mm, NEX = 2, Slice Thickness = 10 mm, Flip Angle
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= 40◦. The T2* relaxation rates were calculated by fitting a mono-exponential signal decay model [27]
using the nonlinear curve fitting function lsqcurvefit of Matlab (R2018b, The MathWorks Inc., Natick,
MA, USA). For each sample, a region of interest was chosen manually.
2.4. Electromagnetic Property Measurements
The electrical conductivity (σ [S/m]) and relative permittivity (e) were measured with open-ended
coaxial probe DAK-12 (v2.4; SPEAG, Zurich, Switzerland) with a ZNC3 vector network analyzer
(Rhode & Schwarz, Munich, Germany). The system calibration was performed using the open and
short, and demineralized water at room temperature as load. The samples were placed in 200 mL
measurement caps (diameter 60 mm, height 85 mm) and measured 8 times in the frequency range of
50–600 MHz with 1 MHz steps at 21 ◦C. The VNA was recalibrated before each measurement.
2.5. Effects on Power Deposition Pattern
The effect of the change in the electromagnetic properties of the WB were evaluated for two
MR compatible hyperthermia applicators: the Sigma Eye applicator of the BSD2000-3D/MR system
(PYREXAR Medical, West Valley City, UT, USA) [28] and our in-house developed MR-compatible
head and neck hyperthermia applicator (MRcollar) [23]. The Sigma Eye consists of 12 dipole antenna
pairs operating at 100 MHz and this device is used for deep loco-regional hyperthermia treatments
in pelvis region. The WB of this applicator encloses the abdominal region of the patient in treatment
configuration. The MRcollar is a twelve-channel applicator and consists of two moon-shaped halves.
Modified Yagi-Uda antennas operating at 434 MHz are employed in this applicator [29]. Hyperthermia
treatment planning was performed for these applicators for models of two patients that were treated
with pelvis or head and neck hyperthermia, respectively. In our simulations, the electromagnetic
properties of the WB were changed to those measured for the different solutions. Electromagnetic field
distributions were computed per antenna using Sim4Life (v.5.0.1, Zurich MedTech, Zurich, Switzerland)
and normalized to 1 W radiated power. Then, the field was optimized using Matlab-based in-house
developed adaptive hyperthermia tool VEDO [30]. The effect on the power deposition patterns were
evaluated using hyperthermia treatment planning (HTP) parameters target-to-hotspot quotient (THQ)
and the target coverage of the 50% iso-SAR volume (TC50) [31,32]. To calculate the effect on power
efficiency, total input power was increased until the maximum predicted temperature in the healthy
tissue reached 44 ◦C. This power was then used to compare the effect of the change in measured
dielectric property for each solution on power efficiency, i.e., heat loss in the WB.
2.6. Effects on MRT Precision
The samples that satisfied the requirements were tested in a representative treatment setup using
the MRcollar. The other MR compatible applicator available in Erasmus MC the Sigma Eye applicator
is in clinical use and the WB cannot be instantly changed, whereas the MRcollar is an experimental
prototype and has exchangeable WB. The WB of the right MRcollar shell was used to test the effect
of these samples. For all cases, the WB of the left MRcollar shell was filled with demineralized water
and the water was not circulated. The in-house developed ADAM phantom (T1: 820 ms; T2: 37 ms),
representing the morphology of an average head and neck patient, was scanned with the clinically
used MRT sequence for deep hyperthermia treatments (SNR 85 dB) [24]: dual echo gradient echo
sequence, 620/4.8/19.1 ms, flip angle 40◦, slice thickness 10 mm, slice spacing 22 mm, 5 slices, FOV
360 × 360 mm2, matrix size 256 × 256, NEX 1. Images were acquired continuously under three
different conditions for a total of 15 min: without water circulation between 0–5 min, during the water
circulation between 5–10 min (maximum flow rate 1.5 L/min), and after water circulation was stopped
between 10–15 min. Furthermore, a reduced FOV (360 × 270 mm2) scan was also tested to show
the potential effects of WB signal aliasing. MRT maps were calculated using the proton resonance
frequency shift method and applying background drift correction using four regions of interest at the
edges of the phantom. Since no heating pulses were applied during the experiment, the expected
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measured temperature change both temporally and spatially was 0 ◦C. Using this assumption, MRT
precision per voxel was calculated by calculating the standard deviation over all PRFS temperature
measurements.
3. Results
In Table 1, a summary of all results is presented. In the following sections, each measurement will
be investigated in detail.
Table 1. T2* at 1.5 T, conductivity and relative permittivity of demineralized water and different
water solutions at 100 and 434 MHz, and their effect on hyperthermia treatment planning parameters
target-to-hotspot quotient (THQ), the target coverage of the 50% iso-SAR volume (TC50 [%]) and
required power to reach 44 ◦C in the healthy tissue (Power [W]) for two different MR compatible RF
hyperthermia devices. T2* values donated with ≈ are not fitted due to low SNR.
MRcollar Sigma Eye
T2* (ms)
at 1.5 T
σ (S/m)
at 434 MHz
e
at 434 MHz THQ
TC50
(%)
Power
(W)
σ (S/m)
at 100 MHz
e
at 100 MHz THQ
TC50
(%)
Power
(W)
Demineralized
Water 120 0.04 79.2 0.43 23 180 0.001 79.1 0.57 11 1201
50 mM
CuSO4 Solution
10.8 0.59 82.1 0.39 22 570 0.495 83.5 0.57 2 9564
100 mM
CuSO4 Solution
6 0.95 84.2 0.32 14 1110 0.831 86.0 0.47 2 23948
250 mM
CuSO4 Solution
3.47 1.85 87.5 0.18 0 4761 1.683 89.7 0.16 0 N/A
500 mM
CuSO4 Solution
1.94 3.03 88.1 0.10 0 N/A 2.849 91.1 0.04 0 N/A
1000 mM
CuSO4 Solution
1.09 4.76 83.5 0.05 0 N/A 4.583 88.7 N/A N/A N/A
1250 mM
CuSO4 Solution
≈ 5.34 79.9 0.04 0 N/A 5.171 85.4 N/A N/A N/A
0.5 mM
MnCl2 Solution
11.47 0.03 78.9 0.42 23 177 0.005 78.1 0.57 12 1185
1 mM
MnCl2 Solution
6.27 0.05 78.9 0.43 22 187 0.017 78.2 0.57 10 1337
2.5 mM
MnCl2 Solution
3.77 0.08 79.0 0.43 22 203 0.051 78.2 0.57 5 1656
5 mM
MnCl2 Solution
2.35 0.14 79.0 0.44 22 230 0.105 78.3 0.58 5 2181
12.5 mM
MnCl2 Solution
1.13 0.29 78.9 0.42 21 325 0.256 78.6 0.57 4 4144
25 mM
MnCl2 Solution
≈ 0.53 79.0 0.40 22 503 0.488 78.8 0.57 2 9734
0.25 mM
Fe3O4 Solution
6.42 0.04 79.2 0.42 22 181 0.001 78.9 0.56 10 1236
0.5 mM
Fe3O4 Solution
4.1 0.04 79.2 0.42 22 179 0.001 78.9 0.57 7 1105
1 mM
Fe3O4 Solution
2.71 0.04 79.2 0.42 23 181 0.001 78.9 0.57 6 1132
2.5 mM
Fe3O4 Solution
1.44 0.04 79.2 0.43 22 183 0.002 78.9 0.57 9 1159
5 mM
Fe3O4 Solution
1.07 0.04 79.2 0.43 22 191 0.003 78.9 0.56 10 1163
10 mM
Fe3O4 Solution
≈ 0.05 79.2 0.43 22 186 0.006 78.9 0.57 7 1158
3.1. MR Relaxometry Measurements
In Figure 1, example magnitude images acquired with multi echo gradient echo sequence at
echo time 1.3 ms for different solutions are shown. Qualitative analysis on MRI images show it is
possible to reach signal void for every compound. The calculated T2* times at 1.5 T are given in Table 1.
The values for 1250 mM CuSO4, 25 mM MnCl2 and 10 mM Fe3O4 solutions were omitted because the
fitting failed due to low SNR. In order to reduce the WB signal to the noise level, at least 5 mM Fe3O4,
12.5 mM MnCl2, or 1000 mM CuSO4 was required.
Sensors 2020, 20, 2946 6 of 12
Figure 1. Grayscale MR magnitude images acquired with multi echo gradient echo sequence for
different MnCl2, Fe3O4, and CuSO4 concentrations at echo time of 1.3 ms. Complete signal suppression
were achieved for each compound for the sample with the highest concentration.
3.2. Electromagnetic Property Measurements
In Figure 2, the change in electrical conductivity in the frequency range of 50–600 MHz is
illustrated. All three compounds show a linear increase in conductivity with concentration. Addition
of Fe3O4 didn’t change the conductivity of demineralized water. However, MnCl2 and CuSO4 had a
larger effect. In the case of highest concentration solutions as compared to the demineralized water,
conductivity was increased 133 times for CuSO4, and 13 times for MnCl2 at 434 MHz. Permittivity of
all solutions were stable and was equal to water relative permittivity in the frequency range (79 ± 0.2
at 434 MHz).
Figure 2. Electrical conductivity over the investigated frequency band for different (a) MnCl2, (b) Fe3O4,
and (c) CuSO4 concentrations. Note that the scale in figure (c) is different.
3.3. Effects on SAR Patterns and Applicator Efficiency
In Figure 3, example predicted SAR patterns achieved for the solutions satisfying the MRI
requirements are shown. In the Figure 3a, the clinical standard demineralized water is visualized.
Using that setup (σ: 0.001 S/m at 100 MHz, σ: 0.04 S/m at 434 MHz), THQ of 0.46 and TC50 of 23% for
the head and neck patient, and THQ of 0.57 and TC50 of 11% for the deep pelvis patient was achieved.
The required power levels to reach maximum efficacy in the treatment were 180 W and 1200 W for
MRcollar and Sigma Eye applicators, respectively. As illustrated in the Figure 3 and reported in Table 1,
although 1000 mM CuSO4 solution (σ: 4.5 S/m at 100 MHz, σ: 4.8 S/m at 434 MHz) is able to nullify
the MRI WB signal, it appears not suitable for hyperthermia purposes due to the high losses. On the
other hand, 5 mM Fe3O4 solution (σ: 0.003 S/m at 100 MHz, σ: 0.04 S/m at 434 MHz) had no effect
on the SAR pattern and required only a small change in power (∆W: −37 W for Sigma Eye and ∆W:
11 W for MRcollar) to achieve maximum effectiveness. Finally, it is possible to reach similar predicted
Sensors 2020, 20, 2946 7 of 12
SAR patterns with a 12.5 mM MnCl2 solution (σ: 0.001 S/m at 100 MHz, σ: 0.04 S/m at 434 MHz).
However, this goes at the cost of additional hot-spots at the skin and total RF-input power needs to be
increased by 3000 W for Sigma Eye and 145 W for MRcollar to achieve the same treatment efficacy.
Figure 3. Predicted SAR distributions for models of patients treated with head and neck (MRcollar) and
deep pelvis (Sigma Eye) hyperthermia when the WB is filled with (a) demineralized water, (b) 1000 mM
CuSO4 solution, (c) 12.5 mM MnCl2 solution, and (d) 5 mM Fe3O4.
Our investigations reported in the previous three sections show that CuSO4 is not a suitable
compound for our aim. On the other hand, both 12.5 mM MnCl2 and 5 mM Fe3O4 solutions
appeared suitable for hyperthermia purposes. As such, these have been experimentally tested in the
treatment setup.
3.4. Effect on MRT Precision
In Figure 4, the MRT and the temperature standard deviation (σ) maps acquired during water
circulation are shown for demineralized water, 12.5 mM MnCl2 solution, and 5 mM Fe3O4 solution.
Note that flow was applied between the 5–10 min. In Table 2, the mean, standard deviation and
maximum temperature errors are given for all three cases before, during and after applying (doped)
water circulation. The temperature precision on average in the phantom when demineralized water
was used in the WB was 0.17 ◦C, 0.70 ◦C, 0.29 ◦C without water circulation, during water circulation,
after water circulation respectively. Hence, the flow severely affects MRT precision. Precision improved
to 0.15 ◦C, 0.16 ◦C, and 0.26 ◦C when the demineralized water was doped with 12.5 mM MnCl2. The
reduction in the FOV made possible by reduction of the signal from the WB further improved precision
to 0.11 ◦C when circulation was on. Figure 4c shows the signal aliasing from the antenna modules
that are filled with demineralized WB, while there is no aliasing from the right WB (left in the image),
which contained MnCl2-doped water. MRT precision was the highest when the 5 mM Fe3O4 solution
was used, i.e., 0.09 ◦C, 0.11 ◦C, and 0.11 ◦C (full FOV: without, during and after circulation), and
0.09 ◦C (reduced FOV: during circulation). Figure 4e clearly shows that, while the signal aliasing
from the antenna modules are visible, the signal from the WB is absent. A similar improvement in
the maximum error values was seen when 5 mM Fe3O4 solution were used instead of demineralized
water and MnCl2 solution. The maximum error values were always found for single voxels at the
phantom – air interfaces, near the right side of the phantom. This error is mainly caused by the steep
phase changes in these interfaces and the partial volume effect. In the clinical scenario, such values are
masked by using maximum temperature difference thresholding.
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Table 2. Mean, standard deviation and maximum temperature errors before water circulation, during
water circulation, after water circulation when demineralized water, 12.5 mM MnCl2 solution, and
5 mM Fe3O4 solution is used in the WB.
Demineralized 12.5 mM MnCl2 5 mM Fe3O4
Water Solution Solution
Full FOV Full FOV Reduced FOV Full FOV Reduced FOV
Before Mean error (◦C) −0.06 −0.06 −0.06
Circulation Std (◦C) 0.17 0.15 0.09
Max error (◦C) 1.28 1.89 −1.36
During Mean error (◦C) 0.04 −0.03 −0.05 −0.13 −0.03
Circulation Std (◦C) 0.70 0.16 0.11 0.11 0.09
Max error (◦C) 41.8 −2.00 −2.05 −1.57 1.32
After Mean error (◦C) 0.20 −0.16 −0.05
Circulation Std (◦C) 0.29 0.26 0.11
Max error (◦C) 28.1 5.40 −2.60
Figure 4. MRT maps and temporal precision map during the water circulation when the applicator
right side WB (left in the image) was filled with (first row (a)) demineralized water; (second (b) & third
row (c)) 12.5 mM MnCl2 solution full and reduced Field of View, respectively; (fourth (d) &fifth (e) row)
5 mM Fe3O4 solution full and reduced Field of View, respectively. In the last column, MRT precision
per voxel during the water circulation is shown. The expected measured temperature change both
temporally and spatially was 0 ◦C. Using this assumption, MRT precision was calculated by calculating
the standard deviation over all PRFS temperature measurements. Note that the applicator left side WB
(right in the image) was always filled with demineralized water for reference.
4. Discussion
In this study, we determined that doping the water in the WB by (5 mM) Fe3O4 satisfies the
needs for MRI signal suppressing while having no effect on the SAR pattern and applicator efficiency.
The concentrations of Fe3O4 used in this study do not change the electromagnetic properties of the
demineralized water, hence the predicted RF-power deposition patterns and efficiency is the same as
in the currently used clinical setup. Local magnetic field inhomogeneity created by Fe3O4 particles
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causes rapid MR signal decay, therefore it is ideal for MRI signal suppression. In our MRI experiments,
this effect resulted in on average 75% improvement in MRT precision. Hence, (1) the substantial
improvements in the MRT precision, (2) the absence of an effect on both the predicted SAR and power
efficiency and (3) its simple use makes adding Fe3O4 the water in the WB a very elegant solution that
can considerably improve MR guided hyperthermia.
Our results show that MnCl2 and CuSO4 can be used for WB signal suppression. However, this
comes at the expense of heating efficiency reduction (at least 80% increase in the total input power is
required). A WB solution including MnCl2 and reducing the FOV improved the MRT precision by 70%
compared to the demineralized water setup. Although this remarkable improvement, energy losses in
the WB are high due to the increase in the conductivity. For the head and neck hyperthermia setup, the
power demands can be supplied by the power amplifiers available in our clinic. However, the power
demands for the deep pelvis hyperthermia applicator is above the total amount that power amplifiers
can provide, and hence, unfeasible. In addition, the increased power loss in the WB put additional
constraints on the cooling of the water in order to keep the patient comfortable. Additional heat stress
caused by the WB is highly unwanted. Lastly, CuSO4 solutions that can nullify MRI signal create a
very lossy medium which leads to unacceptable losses in the WB of the RF hyperthermia applicators.
This paper presents the first comprehensive analysis on the T2 shortening agents to be used in
the WB for MR RF guided hyperthermia treatments. The results of our work demonstrate the ability
of these agents to improve different aspects of the treatment. First, they can reduce temperature
measurement errors caused by the water motion. As it has been demonstrated by our results when the
demineralized water circulated, the flow severely affects the MRT precision. This effect was largely
eliminated with the addition of T2 shortening agents. The reported MRT accuracy of RF hyperthermia
devices are in the range of 1 ◦C [13]. However, there is a clear thermal dose effect relation [33–36]
and hotspots in normal tissues still hamper current treatments. Any gain in temperature monitoring
will allow to adapt heating settings to improve treatment. These studies also suggest that even small
increases in temperature of 0.5 ◦C can lead to improved treatment outcome. Hence, the improvement
by the proposed approach will lead to a clinically relevant improvement in treatment monitoring,
which will improve treatment reporting and can be used for adapting the treatment. Second, the
FOV reduction improves resolution and reduces partial volume effects as well as the scan time, both
of crucial importance. This last point, indeed, may result in a shortening of the scan times, increase
in data sampling rate, or higher temperature precision by altering the sequence parameters (e.g.,
by increasing repetition time). At the same time, Fe3O4 solutions have the same electromagnetic
properties of the demineralized water hence the utilization of these solutions have no direct tradeoffs
for the RF hyperthermia treatments. In addition to these technical improvements, there is another very
important benefit due to the possibility to continue water flow: continuity in the cooling of superficial
tissues of the patient during heating. This will help to reduce superficial hotspots to improve patient
comfort, and consequently will help to reduce patient movements. Moreover, continuous cooling
and improved comfort increase the patient’s tolerance to the hyperthermia treatment and therefore
provides the clinical condition required to maximize thermal dose to each patient.
In this study, we have shown the potential of the T2 shortening agents using numerical modelling
and experimentally in clinically representative setup. However, the actual clinical setup includes
components that is not addressed here; mainly the heating RF signal and involuntary patient motion.
It is known that for example artefacts from introduction of additional frequencies can occur and image
noise increases with increasing power [37]. Although, heating RF signal causes artifacts, its affect will
be equal in all cases. Similarly, involuntary motion such as breathing, bowel movement etc. will affect
all setups equally. Therefore, while our results can be optimistic for real clinical usage, the potential
relative improvement compared to the demineralized water in the WB cannot be underestimated.
The main advantage of the use of demineralized water is its biocompatibility and biodegradability.
Fe3O4 nanoparticles are also biocompatible and used for magnetic hyperthermia treatments [38]. An
unstudied potential issue is long term degradation of the device due to the additive. If this turns
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out to be a problem, all the parts of the device in contact with the circulated fluid (antennas, tubing,
connectors etc.) might need corrosion inhibition, for instance coating.
In our investigation, we focused on MR guided RF hyperthermia treatments but our findings can
also be applied for MR guided HIFU applications. In this case, a WB is used for coupling of acoustic
waves and cooling. Removal of WB signal will result in similar improvements in MRT precision as we
have shown in this study as shown in [22]. Still, the effect of these compounds on acoustic properties
and their effect on losses in the WB should investigated.
5. Conclusions
In this work, we have shown that using Fe3O4 nanoparticles doped water instead of the
demineralized water in WB can be used to improve MR guided RF hyperthermia treatments. First,
MRT precision on average was shown to improve from 0.39 ◦C to 0.09 ◦C using a clinical setup and a
patient representative head and neck phantom. Second, the Fe3O4 concentrations required for MR
signal suppression of the WB do not alter the electromagnetic properties of the water in the working
frequencies of the RF hyperthermia applicators. Besides the possibility of long term impact on the
device, there is no tradeoff in terms of heating and imaging when replacing demineralized water by a
Fe3O4 solution. Last, doping the water with MnCl2 can also provide similar improvements in MRT
precision but it comes with cost of increasing the losses in the WB. In summary, Fe3O4 nanoparticles
doped water bolus improves the MRT precision with no performance tradeoffs and has great potential
to improve RF hyperthermia treatment monitoring under MR guidance.
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Abbreviations
The following abbreviations are used in this manuscript:
RF Radio frequency
MRI Magnetic resonance imaging
MRT Magnetic resonance thermometry
WB Water bolus
IR Inversion recovery
MRgFUS Magnetic resonance guided focused ultrasound surgery
HIFU High intensity focused ultrasound
SPIO Suspending iron oxide nanoparticles
SAR Specific absorption rate
SNR Signal-to-noise ratio
THQ Target-to-hotspot quotinent
TC50 Target coverage of the 50% iso-SAR volume
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